MedPath

Safety and efficacy of Stereotactic Radiotherapy in brain metastasis in case of non small cell lung cancer .

Phase 2
Conditions
Health Condition 1: D024- Carcinoma in situ of respiratory system, unspecified
Registration Number
CTRI/2022/02/040576
Lead Sponsor
AIIMS NEW DELHI
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. NSCLC (pathologic confirmation) with 1-4 brain metastasis all smaller than 3 cm in diameter.

2. Adult patients (>=18 years of age),

3. Eastern Cooperative Oncology Group[ECOG] performance status <=2

4. Graded Prognostic Assessment (GPA) >=1.5

5. All standard tumour-staging procedures necessary to define baseline extracranial disease status

6. Systemic treatment as per institute guidelines and physician discretion.

Exclusion Criteria

1.Pregnant women

2.Inability to complete a magnetic resonance imaging scan with contrast

3.Prior resection of cerebral metastasis

4.Chemotherapy within 7 days of preregistration or planned chemotherapy during the radiotherapy

5.Prior cranial radiotherapy

6.Pacemaker or other MRI non-compatible metal in the body

7.Known allergy to gadolinium

8.Leptomeningeal metastases

9.Lesion located within 5 mm of the optic chiasm or within the brainstem

10.Inability to undergo contrast enhanced computed tomography

11.Inability to give consent

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Intracranial tumour control rates. <br/ ><br>Neuro cognitive decline .Timepoint: Intracranial tumor control rate at 3 months <br/ ><br>Neuro congnitive assessment at 4 weeks.
Secondary Outcome Measures
NameTimeMethod
â?¢Cognitive outcomes for individual cognitive assessments: Defined as a decline of greater than 1 SD from baseline on cognitive tests (all tests are standardized based on published norms and transformed so that higher values represent improved cognition) at the 3-month post treatment evaluation.Timepoint: 3 monnths
© Copyright 2025. All Rights Reserved by MedPath